Signaturefd LLC Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 18th, 2023

Signaturefd LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 66,822 shares of the company’s stock after buying an additional 2,084 shares during the period. Johnson & Johnson comprises approximately 0.3% of Signaturefd LLC’s portfolio, making the stock its 29th largest position. Signaturefd LLC’s holdings in Johnson & Johnson were worth $11,804,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Glassy Mountain Advisors Inc. bought a new position in Johnson & Johnson in the fourth quarter worth about $35,000. Retirement Financial Solutions LLC bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $40,000. TD Capital Management LLC bought a new position in shares of Johnson & Johnson during the third quarter valued at approximately $48,000. Iron Horse Wealth Management LLC increased its stake in shares of Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after purchasing an additional 159 shares in the last quarter. Finally, Cowa LLC bought a new position in shares of Johnson & Johnson during the third quarter valued at approximately $58,000. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $180.00 to $179.00 and set an “equal weight” rating for the company in a research note on Monday, April 10th. Guggenheim assumed coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. UBS Group assumed coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target for the company. Atlantic Securities raised their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research report on Wednesday, January 25th. Finally, SVB Leerink reduced their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $173.07.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $165.67 on Tuesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The company has a market cap of $431.45 billion, a P/E ratio of 24.58, a P/E/G ratio of 2.86 and a beta of 0.53. The firm’s fifty day moving average is $157.46 and its two-hundred day moving average is $167.03. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The firm had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. During the same period in the previous year, the firm posted $2.13 EPS. The business’s quarterly revenue was down 4.4% on a year-over-year basis. As a group, analysts anticipate that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Insider Transactions at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.20% of the company’s stock.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.